Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 0.55 |
| ▸ | TNKS | O95271 | 1/20 | 0.55 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.55 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.55 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3063289 | 1.00 | PARP1 (0.55) | PARP1TNKSTNKS2PARP2PARP3 | |
| SCHEMBL15988440 | 1.00 | PARP1 (0.55) | PARP1TNKSTNKS2PARP2PARP3 | |
| Trifluoroacetic Acid SCHEMBL3069178 | 0.97 | PARP1 (0.53) | PARP1TNKSTNKS2PARP2PARP3 | |
| SCHEMBL15988334 | 0.91 | PARP1 (0.63) | PARP1 | |
| Trifluoroacetic Acid SCHEMBL3073502 | 0.90 | PARP1 (0.58) | PARP1TNKSTNKS2PARP2PARP3 | |
| SCHEMBL15988441 | 0.85 | PARP1 (0.60) | PARP1TNKSTNKS2PARP2PARP3 | |
| SCHEMBL3072268 | 0.85 | PARP1 (0.57) | PARP1 | |
| Trifluoroacetic Acid SCHEMBL3069237 | 0.83 | PARP1 (0.58) | PARP1TNKSTNKS2PARP2PARP3 | |
| SCHEMBL3069184 | 0.82 | PARP1 (0.43) | PARP1TNKSTNKS2PARP2PARP3 | |
| SCHEMBL15988390 | 0.82 | PARP1 (0.54) | PARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268827-B2 | Pyridazinone derivatives as PARP inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA. (IT) | 2012-09-18 | — | — | US | claimed |
| US-20100261709-A1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | MSD ITALIA S.R.L. (IT) | 2010-10-14 | — | — | US | claimed |
| EP-2220073-B1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | MSD ITALIA SRL (IT) | 2014-09-03 | — | — | EP | disclosed |
| US-8268827-B2 | Pyridazinone derivatives as PARP inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA. (IT) | 2012-09-18 | — | — | US | disclosed |
| US-20100261709-A1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | MSD ITALIA S.R.L. (IT) | 2010-10-14 | — | — | US | disclosed |
| EP-2220073-A1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. (IT) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009063244-A1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261709-A1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP2, PARP3 | PARP1 1/4885TNKS 20/4885TNKS2 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.